Clinical trialsCompany release

Immutep reports 81% 12-month disease-free survival in neoadjuvant soft tissue sarcoma trial

IMMUTEP Ltd (IMMP) · Fri 20 Nov 2026

Phase II EFTISARC-NEO data presented at CTOS 2026 support eftilagimod alfa with pembrolizumab and radiotherapy, and Immutep plans a registration-directed study in the second half of 2027.

Immutep presented new survival data on 19 November 2026 from the investigator-initiated Phase II EFTISARC-NEO trial at the CTOS 2026 meeting. The study tests eftilagimod alfa (efti) combined with pembrolizumab and radiotherapy, given before surgery, in patients with high-risk resectable soft tissue sarcoma.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): IMMUTEP Ltd ↗

Article written by VigiEye from the official source (IMMUTEP Ltd). Claims are the company's own. AI-assisted; check the source before acting.